Current technology allows SNPs to be assayed cost-effectively for applications in breeding programs and genetic studies.
The operation complexity and assay cost were also reduced.
Compared with traditional MLA or ELISA methods, the assay takes only half a day and consumes significantly less sample and reagents, which will significantly reduce assay cost and simplify disposal.
Hence, the purpose of this review is to highlight some new strategic directions in DNA detection technologies in order to inspire development of novel molecular diagnostic tools and bio-assay systems with superior reliability, reproducibility, robustness, accuracy and sensitivity at lower assay cost.
Different quantitative standardization methods provide options that balance precision, sensitivity, and assay cost.
The problem of using such a kit, however, is that it would increase the assay cost and turn-around time.
As a result, this can simplify experimental protocols, lower the assay cost, and provide amenability to miniaturisation.
Using only selected direct medical costs for which data is available – the "assay cost" – may lead to invalid cost estimates that exclude potentially important components.
This is because at higher biomarker frequencies, the difference in assay cost makes minimal difference to the overall cost-effectiveness of the screening-treatment pairing.
From a laboratory perspective, Xpert MTB/RIF cost $14.93/sample and the MTBDR plus line probe assay cost $23.46/sample, compared to $16.88/sample using conventional automated liquid culture-based methods.
The cost of screening dominates at low frequencies and strategies to improve cost-effectiveness based on the assay cost, drug cost and the group screened should be considered in these scenarios.
